Research
Lactobacillus johnsonii
15 peer-reviewed studies curated from PubMed and Semantic Scholar.
Studies
Sorted by quality and recency
Validity and safety of ID-JPL934 in lower gastrointestinal symptom improvement.
RCT evaluating the efficacy of ID-JPL934, a probiotic preparation, in relieving lower gastrointestinal symptoms in 112 subjects. The ID-JPL934 group showed higher relief of overall symptoms, including abdominal pain and bloating, compared to placebo. Fecal microbiome profiles did not differ, but qPCR analysis showed increased levels of Lactobacillus johnsonii and Bifidobacterium lactis in the ID-JPL934 group.
A trial of adding Lactobacillus johnsonii EM1 to levocetirizine for treatment of perennial allergic rhinitis in children aged 7-12 years.
RCT comparing levocetirizine with and without Lactobacillus johnsonii EM1 (Lj EM1) in 63 children with perennial allergic rhinitis. The combination of levocetirizine and Lj EM1 was more effective in improving total symptom scores and nasal peak expiratory flow rate than levocetirizine alone. Improvements persisted for at least 3 months after discontinuation of Lj EM1.
Clinical evidence of benefits of a dietary supplement containing probiotic and carotenoids on ultraviolet-induced skin damage.
Three clinical trials assessed the effects of a dietary supplement combining Lactobacillus johnsonii and carotenoids on UV-induced skin damage in healthy women. The supplement prevented decreases in Langerhans cell density, reduced dermal inflammatory cells, and increased MED and skin color intensity, suggesting a protective effect against UV-induced skin damage.
Urinary D-lactate excretion in infants receiving Lactobacillus johnsonii with formula.
Double-blind RCT with 71 infants assessing the risk of D-lactate accumulation from formula containing Lactobacillus johnsonii. After 4 weeks, D-lactate excretion did not differ between formula groups and remained within normal ranges, indicating no increased risk of lactic acidosis.
Supplementation with oral probiotic bacteria protects human cutaneous immune homeostasis after UV exposure-double blind, randomized, placebo controlled clinical trial.
A double-blind, randomized, placebo-controlled clinical trial with 54 healthy volunteers examined the effects of Lactobacillus johnsonii (La1) supplementation on skin immune status after UV exposure. La1 supplementation accelerated the recovery of skin immune homeostasis after UV-induced immunosuppression, as evidenced by the normalization of CD1a expression and recovery of allostimulatory capacity of epidermal cells.
Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn's disease after lleo-caecal resection.
Multicenter RCT evaluating the efficacy of Lactobacillus johnsonii (LA1) on early post-operative endoscopic recurrence of Crohn's disease in 70 patients. The probiotic did not significantly prevent early endoscopic recurrence at 12 weeks after ileo-caecal resection.
Effects of probiotic or prebiotic supplemented milk formulas on fecal microbiota composition of infants.
RCT evaluating the effects of milk formulas supplemented with prebiotic fructo-oligosaccharides or probiotic Lactobacillus johnsonii La1 on fecal microbiota composition in infants. The study found increased fecal Lactobacillus counts in the probiotic group and higher Bifidobacterium counts in all formula groups, similar to breastfed infants.
Ineffectiveness of Lactobacillus johnsonii LA1 for prophylaxis of postoperative recurrence in Crohn's disease: a randomised, double blind, placebo controlled GETAID trial.
RCT testing Lactobacillus johnsonii LA1 for preventing postoperative recurrence in Crohn's disease. At six months, endoscopic recurrence was observed in 49% of the LA1 group and 64% of the placebo group, with no significant difference. LA1 did not prevent endoscopic recurrence.
Favourable effect of regular intake of fermented milk containing Lactobacillus johnsonii on Helicobacter pylori associated gastritis.
RCT of 50 H. pylori positive healthy volunteers comparing fermented milk containing Lactobacillus johnsonii (LC1) to placebo. LC1 intake reduced severity and activity of antral gastritis and decreased H. pylori density in the antrum after 16 weeks. Mucus thickness increased with LC1 consumption.
Suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers.
The study investigates the suppressive effect of frequent ingestion of Lactobacillus johnsonii La1 on Helicobacter pylori colonization in asymptomatic volunteers.
Favourable effect of an acidified milk (LC-1) on Helicobacter pylori gastritis in man.
RCT of 53 volunteers with H. pylori infection testing the effect of L. johnsonii La1-acidified milk (LC-1) on infection. LC-1 ingestion decreased H. pylori density and reduced inflammation and gastritis activity, though it did not enhance the antibiotic effect of clarithromycin.
A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients.
A randomized, double-blind trial investigated the effects of perioperative administration of probiotics in colorectal cancer patients. Lactobacillus johnsonii adhered to the colonic mucosa, reduced pathogen concentration, and modulated local immunity, while Bifidobacterium longum did not adhere.
Improvement of nutritional status and incidence of infection in hospitalised, enterally fed elderly by feeding of fermented milk containing probiotic Lactobacillus johnsonii La1 (NCC533).
Double-blinded feeding trial in 24 enterally fed elderly patients to assess the effect of fermented milk containing Lactobacillus johnsonii La1 on infections and nutritional status. The LC1 group showed a significant decrease in infection days and improvements in blood Hb, serum albumin, and TNF-alpha levels compared to the control group.
Modulation of nonspecific mechanisms of defense by lactic acid bacteria: effective dose.
RCT examining the effect of a fermented milk product containing Lactobacillus johnsonii La1 on phagocytic activity and respiratory burst activity in healthy adults. The product with 10(7) cfu/ml L. johnsonii La1 significantly enhanced both functions, while the product with 10(6) cfu/ml had no significant effect.
Effects of intrajejunal perfusion and chronic ingestion of Lactobacillus johnsonii strain La1 on serum concentrations and jejunal secretions of immunoglobulins and serum proteins in healthy humans.
RCT with 12 healthy volunteers ingesting fermented milk containing Lactobacillus johnsonii La1 or a control for 28 days. Serum IgA concentrations slightly increased in the La1 group, while other parameters remained unchanged. The study suggests immunomodulating effects of La1 ingestion.